1 / 41

Slow viral or prion diseases of the central nervous system

Slow viral or prion diseases of the central nervous system. Slow viral diseases of the central nervous system. tempo of clinical disease protracted incubation period (may also be protracted course of disease) multiple neurological symptoms. SLOW INFECTIONS IN HUMANS. VIRUSES

Antony
Télécharger la présentation

Slow viral or prion diseases of the central nervous system

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Slow viral or prion diseases of the central nervous system

  2. Slow viral diseases of the central nervous system • tempo of clinical disease • protracted incubation period • (may also be protracted course of disease) • multiple neurological symptoms

  3. SLOW INFECTIONS IN HUMANS • VIRUSES • SV40-like viruses (PML) • measles virus (SSPE) • rubella virus (PRP) • ATYPICAL AGENTS • Kuru, • Creutzfeld-Jakob disease (CJD) • (new) variant CJD disease (vCJD=nvCJD)

  4. Progressive multifocal leukoencephalopathy • Polyoma virus family, SV40-like (JC virus etc) • progressive, usually fatal, associated with immune suppression • HAART may prolong life in AIDS patients • but little effect on PML incidence • typically non inflammatory • but can get an inflammatory response in the brain after HAART treatment (immune reconstitution inflammatory syndrome) • demyelination (oligodendrocytes infected)

  5. SYMPTOMS • weakness • speech problems • cognitive problems • headaches • gait problems • visual problems • sensory loss • seizures http://library.med.utah.edu/WebPath/TUTORIAL/AIDS/AIDS076.html

  6. Progressive multifocal leukoencephalopathy • reactivation of latent infection • 70-80% population are seropositive • associated with immunosuppression • 1979: 1.5 per 10,000,000 population • 2004: 1 in 20 AIDS patients

  7. BK virus (polyoma) • Associated with urinary tract infections in immunosuppression • Possibly contributory factor in prostate cancer???

  8. MEASLES VIRUS • paramyxovirus family (morbillivirus genus) • sub-acute sclerosing panencephalitis • inflammatory disease • defective virus • ~1-10 yrs after initial infection • early infection with measles is a risk factor • rare complication of measles (7-70 cases per 1,000,000 cases measles) • vaccine protects against SSPE

  9. RUBELLA VIRUS • togavirus family (rubrivirus genus) • progressive rubella panencephalitis • inflammatory disease • years after initial infection • congenital / very early infections • very very rare

  10. transmissible subacute spongiform encephalopathies transmissible cerebral amyloidoses prion diseases

  11. http://www.cdc.gov/ncidod/dvrd/cjd/ (Ermias Belay)

  12. TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES (TSEs, TRANSMISSIBLE CEREBRAL AMYLOIDOSES, PRION DISEASES) • human • Kuru • Creutzfeldt-Jakob disease (CJD) • Gerstmann-Straussler-Scheinker syndrome (GSS) • fatal familial insomnia (FFI) • variant CJD (‘human BSE’) • animal • scrapie (sheep and goats) • bovine spongiform encephalopathy (BSE) • transmissible mink encephalopathy • etc

  13. ATYPICAL AGENTS • atypical viruses • atypical agents • prions

  14. SIMILAR TO VIRUSES small filterable need host cells no machinery for energy generation or protein synthesis DIFFERENT FROM VIRUSES no detectable virions in infected tissues no detectable virions in purified infectious material if nucleic acid is present, very small very resistant to inactivation ATYPICAL AGENTS

  15. RESISTANT TO OR ONLY PARTIALLY INACTIVATED BY: • formaldehyde • ethanol • glutaraldehyde • ultraviolet and ionizing irradiation • non-ionic detergents • INACTIVATED BY: • autoclaving (121C for one hour) (> standard) • 5% sodium hypochlorite • sodium hydroxide • proteases, urea, other protein denaturants

  16. purified infectious material • protein present (PrP) • proteases inactivate • nucleic acid controversial • but little or none PRION

  17. PRION DISEASE • CNS • LONG INCUBATION • SLOW COURSE OF DISEASE (FATAL) • SPONGIFORM ENCEPHALOPATHY • VACUOLATION OF NEURONS • FIBRILLAR AGGREGATES, AMYLOID-TYPE MATERIAL (form plaques) • RARE IN MAN http://www.cdc.gov/ncidod/dvrd/cjd/ (Ermias Belay)

  18. Helical - Happy Beta-pleated sheet - Bad PRION PROTEIN (PrP)(host cell gene) PrP or PrPC alpha-helical protease sensitive PrPRES or PrPSC beta-pleated sheet protease resistant

  19. PrP + + PrPSC

  20. spontaneous conversion SPORADIC acquired conversion ACQUIRED acquired PrPSC germline mutation, spontaneous conversion more likely INHERITED somatic mutation, spontaneous conversion more likely SPORADIC

  21. WHY ARE DIFFERENT PRION DISEASES DIFFERENT? SEEMS MORE THAN ONE CONFORMATION FOR THE PrPSC FORM

  22. PrP 1 + + PrPSC PrP 2 + + disease caused by conformation 1 may differ from that caused by conformation 2 PrPSC

  23. WHY ARE PRION DISEASES SOMETIMES INHERITED? MUTATIONS IN THE PrP GENE CAN INCREASE THE CHANCE OF PrPSC FORMATION

  24. germline mutation 1 INHERITED germline mutation 2 INHERITED disease caused by germline mutation 1 may differ from that caused by germline mutation 2

  25. SCRAPIE • sheep • loss of muscular control • wasting • glial proliferation • vacuolation of neurons • amyloid plaques • abnormal properties infectious material • does not seem to cross sheep/human species barrier

  26. KURU • human disease • tremors, ataxia, weakness • dementia, death • amyloid plaques • spongiform changes • transmission – contact with infectious material

  27. CREUTZFELDT-JAKOB DISEASE • spongiform appearance of brain at autopsy • dementia, myoclonus, ataxia • 16-80+, usually 50-70 • Median age at death in US=68 yrs • 10% familial • also sporadic form • also acquired form (eg. iatrogenic CJD) • several hundred deaths in US per year

  28. CREUTZFELDT-JAKOB DISEASEclassical form • no evidence for direct person to person transmission • blood • milk • other body fluids • intimate social contact

  29. CREUTZFELDT-JAKOB DISEASE • iatrogenic CJD • human cadaver growth hormone • human cadaver gonadotropin • dural mater grafts • corneal transplantation • neurosurgical instruments • stereotactic EEG electrodes

  30. variant CJD (vCJD) • patients younger at presentation, more protracted course of disease • median age at death for UK vCJD patients=28 yrs • often patients present with psychiatric symptoms • BSE connection • seems bovine/human barrier is easier to cross than sheep/human barrier • distinctive pathological appearance • distinctive properties of the PrPres • agent is in some peripheral tissues • lymphoid tissues • 2 probable cases where transmitted by blood • future? • two cases in US – both had spent time in UK

  31. Belay et al (2005) Emerging Infectious Diseases • www.cdc.gov/eid • 11: 1351

  32. CDC/ Teresa Hammett , Photo Credit: Sherif Zaki; MD; PhD; Wun-Ju Shieh; MD; PhD; MPH

  33. Amino acid 129 Met or Val?- both variants found in the human population • Britain • 37% of the UK population is MM • 100% of clinical vCJD cases are MM • Are MV, VV immune to vCJD, or will they develop vCJD later on? • 83% of sporadic CJD cases are MM • Britain, France, Japan • excess of VV in growth hormone recipients with iatrogenic CJD • does heterozygosity (M/V) offer some protection?

  34. OTHER HUMAN PRION DISEASES • Gerstmann-Sträussler-Scheinker syndrome (GSS) (familial) • motor • sometimes regarded as subclass of CJD • fatal familial insomnia (FFI) • circadian rhythm problems • hypothalamus

  35. IMMUNE RESPONSE • no inflammatory response • no interferon induction • no antibody response • no cell-mediated response

  36. TREATMENT • invariably fatal • attempts at drug therapy disappointing • blood brain barrier

  37. DIAGNOSIS • CLINICAL PICTURE, EEG, MRI (vCJD) • USUALLY CONFIRMED POST-MORTEM • NOW HAVE ANTIBODIES RAISED IN RECOMBINANT MICE • can use on biopsy of brain (or peripheral lymphoid tissue in vCJD)

  38. PLAQUES • PrP • NOT THE SAME AS IN ALZHEIMERS

  39. http://www.cdc.gov/ncidod/dvrd/vcjd/

  40. Belay, E. http://www.cdc.gov/ncidod/dvrd/vcjd/chart_percent_vcjd_cjd_deaths.htm

More Related